Announcements Trials
Browse Landscape

Phase

Phase EARLY_PHASE1 1Phase 2 1Phase 1 1

Status

Completed 14Recruiting 6Withdrawn 4Terminated 3Active not recruiting 2Unknown 1

Sponsor Class

INDUSTRY 2OTHER 1

Study Type

Interventional 3

Sponsor

Cancer Type

Plasma cell 1Other hematologic neoplasm 1Genitourinary 1

Conditions

Recurrence 1Prostatic Neoplasms 1Neoplasms 1Multiple Myeloma 1Leukemia, Large Granular Lymphocytic 1

Interventions

Cyclophosphamide 390Carboplatin 344Gemcitabine 332pembrolizumab 329Cisplatin 328Paclitaxel 297Radiotherapy 296Docetaxel 286Bevacizumab 253Rituximab 234Capecitabine 223Nivolumab 220Dexamethasone 206Fluorouracil 190fludarabine 177Oxaliplatin 177Pemetrexed 153Doxorubicin 153Irinotecan 148Leucovorin 144Etoposide 144Cytarabine 133Cetuximab 129Bortezomib 129fludarabine phosphate 128Lenalidomide 126Erlotinib Hydrochloride 120Filgrastim 119Temozolomide 113Radiosurgery 113

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

3 trials
RecentStart dateEnrollment
Terminated × siltuximab × Clear all
NCT05316116 2026-02-05

Siltuximab in Large Granular Lymphocytic Leukemia (LGLL)

H. Lee Moffitt Cancer Center and Research Institute

Phase EARLY_PHASE1 Terminated
6 enrolled
Other hematologic neoplasm

Leukemia, Large Granular Lymphocytic

NCT00385827 2014-08-20

A Safety and Efficacy Study of Siltuximab (CNTO 328) in Male Subjects With Metastatic Hormone-Refractory Prostate Cancer (HRPC)

Centocor, Inc.

Phase 2 Terminated
106 enrolled 13 charts
Genitourinary

Neoplasms, Prostatic Neoplasms

NCT01309412 2014-05-19

A Phase 1 Study of CNTO 328 (Siltuximab) in Relapsed or Refractory Multiple Myeloma

Janssen Pharmaceutical K.K.

Phase 1 Terminated
9 enrolled
Plasma cell

Multiple Myeloma, Recurrence

Data powered by HemOnc (CC BY 4.0) Colophon âš¡